<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>Insight数据库 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-19T20:48:53+08:00</updated>
  <subtitle>丁香园 Insight 数据库（db.dxy.cn），拥有申报、临床、上市、药企等 10 大核心数据。致力于分享医药行业政策解读、药企大事和药品申报情报等</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>这 59 个新药，获批临床了</title>
    <updated>2021-01-19T17:39:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/A4XDim3ydd1iTtJM45bdIg</id>
    <link href="https://mp.weixin.qq.com/s/A4XDim3ydd1iTtJM45bdIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达「贝伐珠单抗」再次出海，授权 Etana 将达攸同推向印尼市场</title>
    <updated>2021-01-19T17:39:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/VzqkZeOnOuZo9OLO_W0lag</id>
    <link href="https://mp.weixin.qq.com/s/VzqkZeOnOuZo9OLO_W0lag" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>先声药业 CDK4/6 抑制剂获批临床，化疗患者骨髓保护</title>
    <updated>2021-01-19T17:39:15+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/2Cf46BracPsk2PeAbE6FKw</id>
    <link href="https://mp.weixin.qq.com/s/2Cf46BracPsk2PeAbE6FKw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>今日，12 款仿制药获批，5 款仿制药通过一致性评价（附第四批国采最新竞争格局）</title>
    <updated>2021-01-18T17:44:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/-_6t2vwoYO38GZC-mZnBuw</id>
    <link href="https://mp.weixin.qq.com/s/-_6t2vwoYO38GZC-mZnBuw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>专业解读 | 《药品上市后变更管理办法》哪些要点必须注意？</title>
    <updated>2021-01-18T17:44:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/R3H2M6tn9v3bD9TFNV5m_Q</id>
    <link href="https://mp.weixin.qq.com/s/R3H2M6tn9v3bD9TFNV5m_Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个异体 CAR-T 产品启动临床，来自亘喜生物</title>
    <updated>2021-01-18T17:44:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/xZ1_GO4-nASbvAaCVWF_aQ</id>
    <link href="https://mp.weixin.qq.com/s/xZ1_GO4-nASbvAaCVWF_aQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>诺诚健华：3 年亏损 34 亿，为何仍被看好？</title>
    <updated>2021-01-15T16:51:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/ebcMBxmL8Uy6EUuOKfo0Lg</id>
    <link href="https://mp.weixin.qq.com/s/ebcMBxmL8Uy6EUuOKfo0Lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>1.05 亿美元！复宏汉霖获得 Trop-2 抗体中国权益，国内这些企业在研</title>
    <updated>2021-01-15T16:51:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/59_C78QfkUfKZCLhNYm6Cw</id>
    <link href="https://mp.weixin.qq.com/s/59_C78QfkUfKZCLhNYm6Cw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>临床急需！「布罗索尤单抗」获批上市，X 连锁低磷血症</title>
    <updated>2021-01-15T16:51:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/ioLlHc8VxxOPcRoXXLpOxw</id>
    <link href="https://mp.weixin.qq.com/s/ioLlHc8VxxOPcRoXXLpOxw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>长效缓释微球！绿叶制药「注射用利培酮微球（II）」获批上市</title>
    <updated>2021-01-15T16:51:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/2TCX_B0NHXIIgawR2eeTJQ</id>
    <link href="https://mp.weixin.qq.com/s/2TCX_B0NHXIIgawR2eeTJQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>会前通知丨BIO APAC 多的是你不知道的事！</title>
    <updated>2021-01-15T16:51:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/sRGEbwgR3j5OxFA0ldhLig</id>
    <link href="https://mp.weixin.qq.com/s/sRGEbwgR3j5OxFA0ldhLig" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>官宣！百济神州 PD-1 一线鳞状 NSCLC 适应症正式获批，国产首个</title>
    <updated>2021-01-14T12:18:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/Kr2osLLGejv4xG-PHkwWIg</id>
    <link href="https://mp.weixin.qq.com/s/Kr2osLLGejv4xG-PHkwWIg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020 年 12 月 CDE 药品审评报告</title>
    <updated>2021-01-14T12:18:40+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/lvGne-ryPBge6tqVoYRY_w</id>
    <link href="https://mp.weixin.qq.com/s/lvGne-ryPBge6tqVoYRY_w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>丁香园开放医疗数据平台上线！覆盖药、病、诊、科研等 7 大应用场景</title>
    <updated>2021-01-13T14:35:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/DUek6yuiqeiA-6QZZj_7lg</id>
    <link href="https://mp.weixin.qq.com/s/DUek6yuiqeiA-6QZZj_7lg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济/安进合作的 KRAS 抑制剂，拟突破性疗法</title>
    <updated>2021-01-13T14:35:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/EulZawd_LDcOnPZObqizbw</id>
    <link href="https://mp.weixin.qq.com/s/EulZawd_LDcOnPZObqizbw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​中位总生存达 24 个月！「T+A」方案显著改善晚期肝癌患者总生存期</title>
    <updated>2021-01-13T14:35:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-13:/s/qzOfZfVXL6eU_TqpwGG20w</id>
    <link href="https://mp.weixin.qq.com/s/qzOfZfVXL6eU_TqpwGG20w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首款 CAR-T 来了！复星凯特「阿基仑赛注射液」即将获批</title>
    <updated>2021-01-12T13:30:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/5MYn1_iwxAOg8xpIUu4P6w</id>
    <link href="https://mp.weixin.qq.com/s/5MYn1_iwxAOg8xpIUu4P6w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州 PD-1 出海提速！22 亿美元与诺华达成海外授权</title>
    <updated>2021-01-12T13:30:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/0TJVpcarNQQhlbYbh2mbTA</id>
    <link href="https://mp.weixin.qq.com/s/0TJVpcarNQQhlbYbh2mbTA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达生物 PD-1 第 3 项适应症上市申请获受理！二线治疗鳞状 NSCLC</title>
    <updated>2021-01-12T13:30:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/1aSB1DpHhDbY0KazgYdEnQ</id>
    <link href="https://mp.weixin.qq.com/s/1aSB1DpHhDbY0KazgYdEnQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>5 款重磅注射剂品种通过一致性评价！附第四批国采最新竞争格局</title>
    <updated>2021-01-12T13:30:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-12:/s/BjO3EmDM-PxIcwfVAYT5bg</id>
    <link href="https://mp.weixin.qq.com/s/BjO3EmDM-PxIcwfVAYT5bg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>